+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Gallbladder Neoplasms - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • September 2021
  • Region: Global
  • DelveInsight
  • ID: 4330849
UP TO OFF until Dec 31st 2023
This “Gallbladder Neoplasms - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Gallbladder Neoplasms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Gallbladder Neoplasms Understanding

Gallbladder Neoplasms: Overview


Gallbladder carcinoma is a term referring to primary epithelial malignancies arising from the gallbladder, in which the great majority (90%) are adenocarcinomas and the remainder are squamous cell carcinomas. Symptoms of gallbladder neoplasm include abdominal pain, nausea or vomiting, jaundice, general weakness or fatigue, a lump in the abdomen, weight loss, and fever. The diagnosis of gallbladder neoplasms include blood tests and imaging tests like ultrasound, computerized tomography (CT) and magnetic resonance imaging (MRI). Treatment of gallbladder carcinoma depends on the type and stage of cancer. Management of gallbladder carcinoma is primarily surgical.

"Gallbladder Neoplasms - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gallbladder Neoplasms pipeline landscape is provided which includes the disease overview and Gallbladder Neoplasms treatment guidelines. The assessment part of the report embraces, in depth Gallbladder Neoplasms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gallbladder Neoplasms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder Neoplasms R&D. The therapies under development are focused on novel approaches to treat/improve Gallbladder Neoplasms.

Gallbladder Neoplasms Emerging Drugs Chapters


This segment of the Gallbladder Neoplasms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gallbladder Neoplasms Emerging Drugs


Andes-1537: Andes Biotechnologies


Andes-1537 is a proprietary antisense oligonucleotide designed by Andes Biotechnology. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. The drug is in Phase I clinical studies for the treatment of gall bladder cancer and solid tumor.

Seribantumab: Elevation Oncology


Seribantumab is a fully human anti-HER3 (ErbB3) monoclonal antibody, targeting the ErbB3 receptor. Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion-positive gastrointestinal (GI) cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion-driven cancers. The drug is in Phase II clinical studies for the treatment of patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

Gallbladder Neoplasms: Therapeutic Assessment


This segment of the report provides insights about the different Gallbladder Neoplasms drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gallbladder Neoplasms


There are approx. 10+ key companies which are developing the therapies for Gallbladder Neoplasms. The companies which have their Gallbladder Neoplasms drug candidates in the most advanced stage, i.e. Phase II include, Elevation Oncology.

Phases


This report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Gallbladder Neoplasms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gallbladder Neoplasms: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gallbladder Neoplasms therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gallbladder Neoplasms drugs.

Gallbladder Neoplasms Report Insights

  • Gallbladder Neoplasms Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Gallbladder Neoplasms Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Gallbladder Neoplasms drugs?
  • How many Gallbladder Neoplasms drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gallbladder Neoplasms?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gallbladder Neoplasms therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gallbladder Neoplasms and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Andes Biotechnologies
  • Merck
  • Elevation Oncology
  • Leap Therapeutics
  • Ipsen
  • Ohara Pharmaceuticals
  • AstraZeneca
  • Elicio Therapeutics
  • Array BioPharma

Key Products

  • Andes-1537
  • M7824
  • Seribantumab
  • DKN 01
  • Irinotecan sucrosofate
  • ONC 201
  • Tremelimumab
  • ELI 002
  • Tucatinib


This product will be delivered within 2 business days.

Table of Contents

Introduction

Executive Summary

Gallbladder Neoplasms: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Gallbladder Neoplasms - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Seribantumab: Elevation Oncology
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Andes-1537: Andes Biotechnologies
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Gallbladder Neoplasms Key Companies

Gallbladder Neoplasms Key Products

Gallbladder Neoplasms- Unmet Needs

Gallbladder Neoplasms- Market Drivers and Barriers

Gallbladder Neoplasms- Future Perspectives and Conclusion

Gallbladder Neoplasms Analyst Views

AppendixList of Tables
Table 1 Total Products for Gallbladder Neoplasms
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Gallbladder Neoplasms
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Andes Biotechnologies
  • Merck
  • Elevation Oncology
  • Leap Therapeutics
  • Ipsen
  • Ohara Pharmaceuticals
  • AstraZeneca
  • Elicio Therapeutics
  • Array BioPharma